Eisai Pharmaceuticals India Pvt Ltd, which has a unit in the Jawahar Pharma city in Visakhapatnam district, has taken up an expansion project and is also introducing new drugs to the Indian market, according to Managing Director Sanjit Singh Lamba.
The company is increasing its API (active pharma ingredient) plant capacity from 30 tonnes to 100 tonnes by constructing another block and increasing the capacity of the warehouse by the year-end.
Lamba said here on Tuesday, “We will roll out production from the new block from the 2017 financial year.”
The facility at JNPC produces APIs, oral solid dosage form tablets and carries out R&D activity.
He said the Indian subsidiary of the pharma major was hitherto focusing on neurological problems and Azheimer’s disease.
“We have introduced drugs for breast cancer from 2013. We will launch new products for treatment of lung and thyroid cancer and epilepsy in the near future,” he added.
He said the company would launch two brand new drugs with its India-specific approach and also two combination drugs.
He said from the next year, the company had plans to start production of generic drugs at the unit here.
Source : thehindubusinessline.com